COR Stock Analysis: Cencora | NYSE
Medical Distribution | NYSE, USA | Market Cap: 62.973m USD | 12M Return: -0% | US03073E1055 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 375M
EPS Trend: 99.7%
Qual. Beats: 1
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cencora, Inc. (NYSE: COR) is a large-cap U.S. pharmaceutical distribution company operating in the Health Care Distributors sub-industry, sourcing and distributing pharmaceutical products domestically and internationally through two main segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. segment serves a broad customer base, including hospitals, retail and mail-order pharmacies, long-term care providers, and animal health markets, and also offers a wide range of services such as pharmacy management, consulting, clinical trial support, and data analytics for biotech and pharma manufacturers. The International segment focuses on pharmaceutical wholesale, global commercialization, and specialty transportation and logistics for the biopharmaceutical industry, distributing to pharmacies, doctors, health centers, and hospitals worldwide.
Founded in 1871 and headquartered in Conshohocken, Pennsylvania, the company was formerly known as AmerisourceBergen Corporation before rebranding to Cencora, Inc. in August 2023. As one of the largest players in the pharmaceutical distribution value chain, Cencora sits between drug manufacturers and a wide array of healthcare providers, making it a critical intermediary in the supply of medications, specialty products, and animal health goods across multiple end markets.
- GLP-1 drug distribution volumes surge on obesity treatment demand
- Walgreens customer concentration risk as pharmacy retailer struggles
- US Healthcare Solutions margins pressured by generic drug deflation
| Net Income: 2.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.30 > 1.0 |
| NWC/Revenue: -1.16% < 20% (prev -1.62%; Δ 0.46% < -1%) |
| CFO/TA 0.06 > 3% & CFO 4.82b > Net Income 2.62b |
| Net Debt (8.91b) to EBITDA (5.15b): 1.73 < 3 |
| Current Ratio: 0.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.9m) vs 12m ago -0.66% < -2% |
| Gross Margin: 3.71% > 18% (prev 3.06%; Δ 0.65% > 0.5%) |
| Asset Turnover: 421.9% > 50% (prev 428.2%; Δ -6.30% > 0%) |
| Interest Coverage Ratio: 8.20 > 6 (EBIT TTM 4.08b / Interest Expense TTM 497.8m) |
| A: -0.05 (Total Current Assets 55.3b - Total Current Liabilities 59.2b) / Total Assets 83.8b |
| B: 0.11 (Retained Earnings 9.14b / Total Assets 83.8b) |
| C: 0.05 (EBIT TTM 4.08b / Avg Total Assets 78.9b) |
| D: 0.04 (Book Value of Equity 3.05b / Total Liabilities 80.6b) |
| Altman-Z'' = 0.44 = B |
| DSRI: 0.99 (Receivables 25.4b/24.6b, Revenue 333b/317b) |
| GMI: 0.83 (GM 3.06% / 3.71%) |
| AQI: 1.00 (AQ_t 0.31 / AQ_t-1 0.31) |
| SGI: 1.05 (Revenue 333b / 317b) |
| TATA: -0.03 (NI 2.62b - CFO 4.82b) / TA 83.8b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of October 31, 2026, the stock is trading at USD 330.53 with a total of 1,025,145 shares traded. Over the past week, the price has changed by -2.35%, over one month by +7.45%, over three months by +3.94% and over the past year by -0.04%.
Current recommended Stop Loss: 312.60 (which is 5.4% or 2.6 ATR below the current price).
Cencora has received a consensus analysts rating of 4.21. Therefore, it is recommended to buy COR.
- StrongBuy: 7
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 369.1 | 11.7% |
P/E Trailing = 24.5719
P/E Forward = 16.6389
P/S = 0.1892
P/B = 20.7029
P/EG = 0.693
Revenue TTM = 333b USD
EBIT TTM = 4.08b USD
EBITDA TTM = 5.15b USD
Long Term Debt = 11.4b USD (from longTermDebt, last quarter)
Short Term Debt = 279.2m USD (from shortTermDebt, last quarter)
Debt = 11.7b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.91b USD (calculated: Debt 11.7b - CCE 2.82b)
Enterprise Value = 71.9b USD (63.0b + Debt 11.7b - CCE 2.82b)
Interest Coverage Ratio = 8.20 (Ebit TTM 4.08b / Interest Expense TTM 497.8m)
EV/FCF = 17.70x (Enterprise Value 71.9b / FCF TTM 4.06b)
FCF Yield = 5.65% (FCF TTM 4.06b / Enterprise Value 71.9b)
FCF Margin = 1.22% (FCF TTM 4.06b / Revenue TTM 333b)
Net Margin = 0.79% (Net Income TTM 2.62b / Revenue TTM 333b)
Gross Margin = 3.71% ((Revenue TTM 333b - Cost of Revenue TTM 320b) / Revenue TTM)
Gross Margin QoQ = 4.26% (prev 4.24%)
Tobins Q-Ratio = 0.86 (Enterprise Value 71.9b / Total Assets 83.8b)
Interest Expense / Debt = 4.25% (Interest Expense 497.8m / Debt 11.7b)
Taxrate = 26.82% (967.3m / 3.61b)
NOPAT = 2.99b (EBIT 4.08b * (1 - 26.82%))
Current Ratio = 0.93 (Total Current Assets 55.3b / Total Current Liabilities 59.2b)
Debt / Equity = 3.84 (Debt 11.7b / totalStockholderEquity, last quarter 3.05b)
Debt / EBITDA = 1.73 (Net Debt 8.91b / EBITDA 5.15b)
Debt / FCF = 2.19 (Net Debt 8.91b / FCF TTM 4.06b)
Total Stockholder Equity = 2.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.33% (Net Income 2.62b / Total Assets 83.8b)
RoE = 106.4% (Net Income TTM 2.62b / Total Stockholder Equity 2.47b)
RoCE = 29.36% (EBIT 4.08b / Capital Employed (Equity 2.47b + L.T.Debt 11.4b))
RoIC = 13.54% (NOPAT 2.99b / Invested Capital 22.1b)
WACC = 4.28% (E(63.0b)/V(74.7b) * Re(4.50%) + D(11.7b)/V(74.7b) * Rd(4.25%) * (1-Tc(0.27)))
Discount Rate = 4.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.10 | Cagr: -1.61%
[DCF] Terminal Value 77.97% ; FCFF base≈2.89b ; Y1≈3.32b ; Y5≈4.88b
[DCF] Fair Price = 338.2 (EV 73.4b - Net Debt 8.91b = Equity 64.5b / Shares 190.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.69 | EPS CAGR: 14.19% | SUE: 1.10 | # QB: 1
Revenue Correlation: 98.53 | Revenue CAGR: 9.29% | SUE: 0.36 | # QB: 0
EPS current Quarter (2026-12-31): EPS=4.58 | Chg30d=-0.42% | Revisions=-17% | Analysts=8
EPS current Year (2026-09-30): EPS=17.88 | Chg30d=+0.04% | Revisions=+77% | GrowthEPS=+11.8% | GrowthRev=+4.9%
EPS next Year (2027-09-30): EPS=19.76 | Chg30d=-0.21% | Revisions=+0% | GrowthEPS=+10.5% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +50% (up=12, down=3)